Translational Research Institute
Latest From Translational Research Institute
With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.